Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes. - Wikidata - awgldk - TriplyDB

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes.

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes.

http://www.wikidata.org/entity/Q36798680

about

Safety and efficiency of SGLT2 inhibitor combining with insulin in subjects with diabetes: Systematic review and meta-analysis of randomized controlled trials.The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis Sodium-glucose co-transporter-2 inhibitors and euglycemic ketoacidosis: Wisdom of hindsight.SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice.Management of Severe Insulin Resistance in Patients with Type 1 Diabetes.Sotagliflozin as a potential treatment for type 2 diabetes mellitus.Insulin resistance, role of metformin and other non-insulin therapies in pediatric type 1 diabetes.Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature.Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus.Intestinal SGLT1 in metabolic health and disease.Addressing Unmet Medical Needs in Type 1 Diabetes: A Review of Drugs under Development.SGLT2 inhibitors in the management of type 2 diabetes.Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials.Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus.Past and current perspective on new therapeutic targets for Type-II diabetes.Dapagliflozin for the treatment of type 1 diabetes mellitus.Weight Management in Patients with Type 1 Diabetes and Obesity.Moving beyond subcutaneous insulin: the application of adjunctive therapies to the treatment of type 1 diabetes.Status of Diabetes Care: New Challenges, New Concepts, New Measures--Focusing on the Future!8th Annual Symposium on Self-Monitoring of Blood Glucose (SMBG): April 16-18, 2015, Republic of Malta.Glycemic Variability Percentage: A Novel Method for Assessing Glycemic Variability from Continuous Glucose Monitor Data.Type 1 diabetes: where are we in 2017?Efficacy of ipragliflozin as monotherapy or as add-on therapy with other oral antidiabetic medications for treating type 2 diabetes in Japanese patients with inadequate glycemic control: A subgroup analysis based on patient characteristics.Efficacy and safety of sotagliflozin in treating diabetes type 1.Progress in Diabetes Technology: Developments in Insulin Pumps, Continuous Glucose Monitors, and Progress towards the Artificial Pancreas.Pharmacological Treatment in Diabetes Mellitus Type 1 - Insulin and What Else?Type 2 treatments for type 1 diabetes.The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes.Adjunctive therapy for glucose control in patients with type 1 diabetes.Altered pancreatic islet morphology and function in SGLT1 knockout mice on a glucose-deficient, fat-enriched diet.Metabolic Control in Type 1 Diabetes: Is Adjunctive Therapy the Way Forward?Does a gluten-free diet determine the efficacy of sotagliflozin in patients with concomitant type 1 diabetes mellitus and celiac disease?SGLT inhibitor adjunct therapy in type 1 diabetes

P2860

Q33760535-249925C8-EF9C-41A6-94D0-391209F026C5 Q36301818-CFE790CC-09A8-4322-A255-9BE43BF86596 Q36357997-64063B86-1CC8-4E22-A8DE-FE49501B1340 Q36372598-6983E4C7-B813-49A7-AC33-4703BA98489C Q38570757-F313BF2B-B84B-4B92-BE42-CCDC06AFD89B Q38628037-7772DBB8-6D62-4663-9B7E-4DCFB9C0558C Q38642435-0BE4E87A-25E4-4B60-BCEB-F9FECE74E03D Q38778239-B707F0C0-4AD0-4350-8579-3604521FB3A9 Q38783130-17E7C6C9-F2F1-4CB9-8E2B-ADC7CC497012 Q38787917-B8CCC081-6178-4D2A-951E-8B26DC1D9D4F Q38806457-7A59E311-FC5D-4EB6-B133-9A5728C6FFA7 Q38857523-2C6A8795-BB83-4E9B-9F23-721112238DD3 Q38863649-4C8CD63E-8214-4B2D-B4D9-846FB3380166 Q39300071-BF64F798-1BDC-400A-9E9D-B29C1BAB1D53 Q39349756-C198DC50-7EB3-49B3-8810-BBFFA98621F1 Q39354776-6D399E31-B573-486B-85AA-37C177E08759 Q41504692-3B190E4F-9FD3-4F7F-A9AD-CB5748EB9223 Q42008289-9E3BF72C-E78C-48F4-A4CA-ACCF84C56DB2 Q42360594-BD242015-45C4-4ED9-9BAF-C9F8F75B71A9 Q42625616-B9154DF1-30A6-4F2A-938F-E6FCBD1958A8 Q46185031-4546D2F5-D60A-4603-B938-016C40902BFA Q47158147-FB29D2DF-25F2-4004-A433-1D796F4B9AC7 Q47995019-F1281DBF-C8A1-49D2-9497-C4A822C7EA9D Q50047534-1E0C36B4-F5F7-4363-A70A-4F40E5FB160C Q51654262-22AB20B0-6E4D-4B13-BA51-DE598047DA59 Q52562630-8D21E59B-2B92-4276-A79F-48503BE066EE Q53751922-9A2CB959-D225-4078-B851-9837598C364A Q53757094-FF07F6DA-6D37-4C0E-8B17-37D17CF2A128 Q55234623-DF1A17F9-A92A-4B95-AF54-5CDB78C9E4B9 Q55516133-6451B11A-9E51-4FD3-A461-5AF9D6886F8A Q57157897-8C55312C-3DC2-457F-9FBF-182BAF427813 Q57301717-42913EDB-5716-4608-A896-8F7260FF2948 Q58718282-AC317E46-3C07-41BC-9EB2-3CCEC710F08D

P2860

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes.

http://www.wikidata.org/entity/Q36798680

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Sotagliflozin, a Dual SGLT1 an ...... to Insulin in Type 1 Diabetes.

@en

type

label

Sotagliflozin, a Dual SGLT1 an ...... to Insulin in Type 1 Diabetes.

@en

prefLabel

Sotagliflozin, a Dual SGLT1 an ...... to Insulin in Type 1 Diabetes.

@en

P1433

Q36798680-8FB8F885-8E71-4D56-9623-3B4CFFF8FBFE

P1476

Q36798680-469FEB25-C45C-4355-B323-435471A66ABA

P2093

Q36798680-0EF7E214-B90B-4970-A53A-3D04EC343C7E

Q36798680-438FBEA6-5170-4AE6-AA18-4DC728268060

Q36798680-6B8C2FC7-AF32-4534-86D4-67E65F38F213

Q36798680-6DAF91EF-EA20-4C28-9C7E-B0A75BB7C2CA

Q36798680-94BF2AAF-616A-4D6F-99B2-E02D5ACEF7B3

Q36798680-B14649C6-2EBA-47C1-9C37-A8A3A678E6E4

Q36798680-C550DE93-5BD8-4AA1-8A4B-7105744E8BEB

Q36798680-E39A89CF-6EFA-48CC-A43A-40637C70BAE8

Q36798680-EF3B8A81-4C49-44C1-BDF7-4431FD164CDD

P2860

Q36798680-01B189ED-9991-4C2E-94ED-66FE0EDD54E5

Q36798680-156D675B-E512-4DDC-8CBC-1183FEDFE2EC

Q36798680-20A33058-7F61-49B4-BEA1-C69B2893F0EE

Q36798680-245727F1-22C1-4C07-9501-BEEBC5E0C6BF

Q36798680-300C78E4-396D-428A-B757-962F5E046695

Q36798680-33483646-0103-489B-A496-B870F1109EE9

Q36798680-55811DAD-1E7E-471A-BF2F-93C73999D177

Q36798680-5B44B6E9-6B60-44B9-99FB-27E789E16330

Q36798680-69327665-C19B-44D8-A574-6D3D2B400E02

Q36798680-6E1F3416-DB02-48DE-AB39-8B5BFB4CAC01

P304

Q36798680-61AC7A5B-5CD4-45D4-A390-549785787A3D

P31

Q36798680-28F8DAAB-B348-49D4-BDC7-EA803FA9F834

P356

Q36798680-3C5C57C2-7106-4848-B883-367C98325572

P407

Q36798680-1E9DF41C-E4E3-4F14-9A7A-55385D827D5B

P433

Q36798680-AFA14A74-745F-401D-BC41-4CD461D83694

P478

Q36798680-2ED2495F-7D58-41DA-8D0B-0631CE40153E

P50

Q36798680-28E1297E-D5F1-4027-80D8-82F54B978534

Q36798680-31ECC7FA-9224-490D-BBC6-FDA148988D67

Q36798680-473155C4-CD15-4450-9B65-7388A3E261C7

P577

Q36798680-751FA95F-C0C8-46D1-85A8-7DA6F53CA121

P5875

Q36798680-71F4CEE6-F5F4-45B3-AF5A-9F3EFDFCB507

P698

Q36798680-89F68F29-CCCB-4C4A-AB8A-F071515425FE

P921

Q36798680-3A3B3C38-2ED0-4BB5-875D-33D54CD34E90

P932

Q36798680-6D2539A1-CA85-4A3F-A772-E0ECA5382705

P356

P1433

P1476

Sotagliflozin, a Dual SGLT1 an ...... to Insulin in Type 1 Diabetes.

@en

P2093

Arthur T Sands

http://www.w3.org/2001/XMLSchema#string

Brian P Zambrowicz

http://www.w3.org/2001/XMLSchema#string

Bruce W Bode

http://www.w3.org/2001/XMLSchema#string

Marc Rendell

http://www.w3.org/2001/XMLSchema#string

Pablo Lapuerta

http://www.w3.org/2001/XMLSchema#string

Paul Strumph

http://www.w3.org/2001/XMLSchema#string

Phillip Banks

http://www.w3.org/2001/XMLSchema#string

Rubina Heptulla

http://www.w3.org/2001/XMLSchema#string

Satish K Garg

http://www.w3.org/2001/XMLSchema#string

P2860

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

Biology of incretins: GLP-1 and GIP

Calculating the mean amplitude of glycemic excursion from continuous glucose monitoring data: an automated algorithm.

Severe hypoglycemia and diabetic ketoacidosis among youth with type 1 diabetes in the T1D Exchange clinic registry

Gut hormone PYY(3-36) physiologically inhibits food intake.

Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry.

Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function.

LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial.

Long-term effect of diabetes and its treatment on cognitive function.

Glycemia and cardiovascular disease in type 1 diabetes mellitus.

P304

1181-1188

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC14-2806

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

38

http://www.w3.org/2001/XMLSchema#string

P50

Julio Rosenstock

William T. Cefalu

P577

2015-06-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

279211093

http://www.w3.org/2001/XMLSchema#string

P698

26049551

http://www.w3.org/2001/XMLSchema#string

P921

type-1 diabetes

P932

4831906

http://www.w3.org/2001/XMLSchema#string